Bone anabolic agents repair alveolar bone damaged by diabetes in mice.
In diabetic mice, abaloparatide increased bone formation without enhancing resorption, suggesting a potential for improving alveolar bone health. However, these results need to be validated in human studies.
Where it sits
this study against the rest of the abaloparatide (tymlos) corpusSummary and findings
This study investigated the effects of the bone anabolic agents parathyroid hormone (PTH) and abaloparatide (ABL) on alveolar bone in a mouse model of type 2 diabetes (T2D). In T2D mice, ABL increased bone formation without enhancing resorption, leading to net alveolar bone gain. No net change in alveolar bone mass was observed in non-diabetic mice treated with PTH and ABL.
Abstract
Type 2 diabetes (T2D) is a chronic metabolic disorder that significantly impacts skeletal health, including bones of the oral cavity, where alveolar bone is particularly susceptible due to its high remodeling rate and sensitivity to systemic metabolic changes. Using a mouse model of established T2D induced by high-fat diet and streptozotocin, we investigated the effects of the FDA-approved bone anabolic agents parathyroid hormone (PTH) and abaloparatide (ABL) on alveolar bone. In non-diabetic mice, PTH and ABL stimulated both bone formation and resorption, resulting in no net change in alveolar bone mass. In contrast, these agents selectively increased bone formation in T2D mice without further enhancing the already elevated resorption, leading to net alveolar bone gain. This anabolic effect involves suppression of sclerostin and Dickkopf-1 (Dkk-1) in osteocytes and activation of Wnt signaling in periodontal ligament cells. Studies using DMP1-Cre;PTH1R<sup>fl/fl</sup> mice demonstrated that osteocytic PTH1R is essential for the anabolic effects but not for the bone resorption-promoting effects of PTH and ABL. These findings reveal a dual mechanism of PTH1R signaling in oral bone remodeling and suggest therapeutic strategies to restore alveolar bone and improve tooth retention and implant osseointegration in diabetic patients.
Background
This paper addresses the impact of type 2 diabetes on skeletal health, particularly the alveolar bone, which is sensitive to metabolic changes. Prior research has shown that diabetes can adversely affect bone remodeling. The study is significant as it explores the potential of FDA-approved bone anabolic agents to counteract these effects in a diabetic model.
Methods
The study utilized a mouse model of established T2D induced by a high-fat diet and streptozotocin. The agents tested were parathyroid hormone (PTH) and abaloparatide (ABL). The primary outcome measured was the change in alveolar bone mass, with secondary outcomes including bone formation and resorption rates.
Results
In non-diabetic mice, PTH and ABL resulted in no net change in alveolar bone mass. In T2D mice, these agents increased bone formation without further enhancing resorption, leading to net alveolar bone gain. Specific mechanisms involved suppression of sclerostin and Dkk-1 and activation of Wnt signaling.
Interpretation
The findings suggest that PTH and ABL may have a unique role in enhancing bone formation in diabetic conditions without increasing resorption. However, the clinical significance of these findings remains uncertain, particularly due to the use of a mouse model, which limits direct applicability to human patients. The study's design and results warrant cautious interpretation regarding potential therapeutic strategies.
Key findings
- In non-diabetic mice, PTH and ABL resulted in no net change in alveolar bone mass.
- In T2D mice, PTH and ABL selectively increased bone formation without further enhancing resorption, leading to net alveolar bone gain.
- Suppression of sclerostin and Dickkopf-1 (Dkk-1) in osteocytes was involved in the anabolic effect.
- Activation of Wnt signaling in periodontal ligament cells was observed.
- Osteocytic PTH1R is essential for the anabolic effects of PTH and ABL.
Limitations
- Mouse model may not fully translate to human conditions.
- Small sample size not reported.
- Short duration of study.
- No clinical data provided.